M
Matthew T. Seymour
Researcher at University of Leeds
Publications - 223
Citations - 12857
Matthew T. Seymour is an academic researcher from University of Leeds. The author has contributed to research in topics: Colorectal cancer & Irinotecan. The author has an hindex of 51, co-authored 216 publications receiving 11007 citations. Previous affiliations of Matthew T. Seymour include Leeds Teaching Hospitals NHS Trust & National Health Service.
Papers
More filters
Journal ArticleDOI
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothyn Stanley Maughan,Richard Adams,Christopher Smith,A Meade,Matthew T. Seymour,Richard H. Wilson,Shelley Idziaszczyk,Rebecca Harris,David Fisher,S Kenny,Edward Kay,Jenna K. Mitchell,A Madi,Bharat Jasani,Michelle D. James,John Bridgewater,M. John Kennedy,Bart Claes,Diether Lambrechts,Richard Kaplan,Jeremy Peter Cheadle +20 more
TL;DR: This trial has not confirmed a benefit of addition of cetuximab to oxaliplatin-based chemotherapy in first-line treatment of patients with advanced colorectal cancer, with no evidence of benefit in progression-free or overall survival in KRAS wild-type patients or even in patients selected by additional mutational analysis of their tumours.
Journal ArticleDOI
Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
Gordon G A Hutchins,K Southward,Kelly Handley,Laura Magill,C Beaumont,Jens Stahlschmidt,Susan D. Richman,Philip A. Chambers,Matthew T. Seymour,David J. Kerr,Richard Gray,Philip Quirke +11 more
TL;DR: The usefulness of defective mismatch repair, BRAF, and KRAS mutations in predicting tumor recurrence and sensitivity to chemotherapy is investigated and MMR assays identify patients with a low risk of recurrence.
Journal ArticleDOI
The prevalence and outcomes of frailty in older cancer patients: a systematic review
C. Handforth,Andrew Clegg,Caroline Young,Samantha A Simpkins,Matthew T. Seymour,Peter Selby,John Young +6 more
TL;DR: The findings of this review support routine assessment of frailty in older cancer patients to guide treatment decisions, and the development of multidisciplinary geriatric oncology services.
Journal ArticleDOI
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman,Matthew T. Seymour,Philip A. Chambers,Faye Elliott,Catherine Daly,Angela M. Meade,Graham R. Taylor,Jennifer H. Barrett,Philip Quirke +8 more
TL;DR: There is no evidence that patients with KRAS/BRAF mutated tumors are less likely to benefit from these standard chemotherapy agents and mutation status did not affect the impact of irinotecan or oxaliplatin on PFS or OS.
Journal ArticleDOI
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Matthew T. Seymour,Tim Maughan,Jonathan A. Ledermann,C. Topham,Roger D James,Stephen J. Gwyther,David Smith,Stephen F Shepherd,Anthony Maraveyas,D. R. Ferry,A Meade,L.C. Thompson,Gareth Griffiths,Mahesh K. B. Parmar,Richard Stephens +14 more
TL;DR: The data challenge the assumption that, in this non-curative setting, maximum tolerable treatment must necessarily be used first-line in patients with advanced colorectal cancer, and suggest the staged approach of initial single-agent treatment upgraded to combination when required is not worse than first- line combination.